Mount Sinai’s new AI replaces weeks of manual review, scanning records in real-time to find trial patients instantly


 A leading cancer center in New York has deployed a specialized artificial intelligence platform to solve the persistent problem of low enrollment in clinical trials. The system uses a large language model trained specifically on oncology data to scan electronic health records in real time. Unlike general AI tools this model understands complex cancer terminology including specific biomarkers and treatment histories hidden in unstructured doctor notes. By automating the screening process the technology identifies eligible patients the moment they qualify replacing the slow and fragmented manual review that often causes patients to miss out on experimental therapies. Clinicians report that the tool drastically reduces the administrative burden allowing them to focus on discussing meaningful treatment options with patients rather than sifting through paperwork. This deployment marks a significant step toward making access to advanced cancer research faster and more equitable.

Read the original article at: https://hitconsultant.net/2026/01/08/mount-sinai-deploys-ai-powered-clinical-trial-matching-platform-to-expand-access-to-cancer-research/


Follow us on Instagram, Twitter, and Facebook to stay up to date with what's new in healthcare all around the world.

Comments

Post a Comment

Popular posts from this blog

Guesswork gone. A new scoring system (ST-RADS) predicts soft-tissue tumor malignancy with 99.2% accuracy.

Image
 Radiologists may soon have a powerful new standard for evaluating soft-tissue tumors. A study detailed in Radiology Business introduces "ST-RADS" (Soft-Tissue Tumor Reporting and Data System), a structured MRI scoring framework designed to replace the often vague descriptive reports currently in use. In a validation study involving roughly 200 patients, the ST-RADS system demonstrated exceptional precision, achieving a 99.2% accuracy rate in predicting malignancy—significantly outperforming the 92.8% accuracy of standard radiological reports. Crucially, the system was perfect (100% accuracy) in identifying benign tumors, a capability that could drastically reduce unnecessary biopsies and patient anxiety. By standardizing how these complex images are interpreted, ST-RADS offers a clear, objective roadmap for clinicians, ensuring that aggressive cancers are flagged immediately while harmless lumps are safely monitored without invasive intervention. Read the original artic...
Read more

The system is too slow. New data reveals that missed "waiting time" targets are hiding the true, deadly cost of cancer care.

Image
 A critical new analysis argues that current targets for cancer treatment waiting times are failing patients and obscuring the true extent of delays. The report highlights that arbitrary benchmarks such as the 62 day target from referral to treatment are frequently missed and do not account for the increasing complexity of modern cancer care. Patients requiring multiple diagnostic tests often face much longer waits that are not accurately reflected in official data. These delays are not merely administrative nuisances they significantly increase the risk of mortality.  The authors contend that simply setting stricter targets is ineffective without addressing the underlying lack of resources. Instead they call for a national learning system driven by data and collaboration to identify bottlenecks in real time and prioritize patients based on clinical urgency rather than outdated metrics. Read the original article at: http://www.bmj.com/content/392/bmj.s14.short?rss=1 Follow ...
Read more

Digital Oncology Insights: 4th December - 10th December

Image
  1. CTCeptor technology simultaneously isolates tumor cells and fibroblasts for better diagnosis. Diagnosing cancer accurately is often difficult because standard liquid biopsies can miss important cells hiding in the blood. To solve this, researchers at DGIST have developed "CTCeptor," a new technology that captures both circulating tumor cells and the "helper" cells (fibroblasts) that support cancer growth. Most current tests try to filter cells based on their size or specific markers, but they often fail to catch cancer cells that look slightly different. CTCeptor uses a unique extraction method that successfully isolates these cells regardless of their size, providing a much more complete picture of the disease. The impact of this technology on patient care could be profound. In recent trials with breast cancer patients, CTCeptor detected 15 times more tumor cells than existing methods. By analyzing both the cancer cells and their environment, doctors can b...
Read more